Switching from antipsychotics to SEP-363856 in schizophrenia care
About this title
Read the official source — NCT05628103Researchers studied SEP-363856, tracking side effects to assess safety and tolerability in people with schizophrenia.
Understand this study
What did researchers investigate?
Researchers studied SEP-363856, tracking side effects to assess safety and tolerability in people with schizophrenia.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Anaheim and 24 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
- Recruitment status
- Completed
- Enrollment listed in the registry
- 101
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT05628103
- Official title
Show the full official title
An 8-Week, Open-Label Study Evaluating the Effectiveness, Safety and Tolerability of SEP-363856 in Subjects With Schizophrenia Switched From Typical or Atypical Antipsychotic Agents
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
Anaheim · Bellflower · Culver City
19 more locations
- Garden Grove
- Lemon Grove
- Riverside
- San Diego
- Santee
- Torrance
- Hollywood
- Miami
- Orlando
- Atlanta
- Chicago
- Gaithersburg
- St Louis
- Las Vegas
- Berlin
- Charlotte
- Hickory
- Garfield Heights
- Richardson
Interested in joining this study?
Questions about this study
What did researchers investigate?
Researchers studied SEP-363856, tracking side effects to assess safety and tolerability in people with schizophrenia.
Who is behind this study?
The study sponsor is Otsuka Pharmaceutical Development & Commercialization, Inc., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including SEP-363856.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
